<DOC>
	<DOCNO>NCT00900354</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory patient cancer receive dactinomycin may help doctor learn dactinomycin work body patient respond treatment . PURPOSE : This laboratory study evaluate pharmacokinetics dactinomycin young patient cancer .</brief_summary>
	<brief_title>Pharmacokinetics Dactinomycin Young Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine pharmacokinetics ( PKs ) dactinomycin pediatric patient cancer . - Determine degree interpatient variation PKs drug . - Determine influence characteristic age , tumor type , concurrent therapy drug PKs patient . - Correlate drug PKs clinical response toxicity observe patient , focus particularly incidence severe liver toxicity veno-occlusive disease . - Correlate pharmacogenetic variability clinical PK data . OUTLINE : This multicenter study . Patients undergo blood collection pharmacokinetic sampling dactinomycin baseline ( prior initiation dactinomycin ) periodically course 1 chemotherapy . An additional blood sample obtain treatment collection peripheral blood lymphocyte . DNA cell isolate investigated genetic variation gene relevant pharmacology dactinomycin . Plasma concentration dactinomycin determine liquid chromatography mass spectrometry analysis . Patients follow 2 year . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer Currently treat dactinomycin clinical trial United Kingdom Children 's Cancer Study Group center PATIENT CHARACTERISTICS : Single doublelumen central venous catheter portacath place PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>